Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus KLOR CON M15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus KLOR CON M15.
K+8 vs KLOR-CON M15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Potassium is the major intracellular cation; it is necessary for conduction of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, maintenance of normal renal function, acid-base balance, and carbohydrate metabolism.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
Oral: 15 mEq (1 tablet) once daily or as directed; range 15-100 mEq/day divided doses. Maximum 150 mEq/day.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Not applicable; potassium is not eliminated by first-order kinetics. Serum potassium decline depends on redistribution and renal function, with a half-life of approximately 1-1.5 hours for acute redistribution but prolonged in renal impairment.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Renal: >90% as potassium ions; fecal: <5%; biliary: negligible.
Category C
Category C
Potassium Supplement
Potassium Supplement